Vera Therapeutics Inc [VERA] stock is trading at $35.98, up 3.27%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VERA shares have gain 6.77% over the last week, with a monthly amount drifted -14.17%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vera Therapeutics Inc [NASDAQ: VERA] stock has seen the most recent analyst activity on January 28, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $58. Previously, Wells Fargo started tracking the stock with Overweight rating on November 21, 2024, and set its price target to $70. On October 16, 2024, Scotiabank initiated with a Sector Outperform rating. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $26 on January 25, 2024. Cantor Fitzgerald initiated its recommendation with a Overweight. Raymond James started tracking with a Outperform rating for this stock on December 18, 2023, and assigned it a price target of $29. In a note dated November 10, 2023, Jefferies upgraded an Buy rating on this stock and boosted its target price from $18 to $26.
Vera Therapeutics Inc [VERA] stock has fluctuated between $29.33 and $51.61 over the past year. Currently, Wall Street analysts expect the stock to reach $26 within the next 12 months. Vera Therapeutics Inc [NASDAQ: VERA] shares were valued at $35.98 at the most recent close of the market. An investor can expect a potential drop of -27.74% based on the average VERA price forecast.
Analyzing the VERA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.5 and Total Capital is -0.42. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 34.74 points at the first support level, and at 33.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 37.36, and for the 2nd resistance point, it is at 38.75.
Ratios To Look Out For
For context, Vera Therapeutics Inc’s Current Ratio is 13.60. Also, the Quick Ratio is 13.60, while the Cash Ratio stands at 1.03.
Transactions by insiders
Recent insider trading involved Fordyce Marshall, PRESIDENT AND CEO, that happened on Jan 08 ’25 when 17500.0 shares were sold. Director, MARSHALL FORDYCE completed a deal on Jan 08 ’25 to buy 17500.0 shares. Meanwhile, PRESIDENT AND CEO Fordyce Marshall sold 17500.0 shares on Dec 18 ’24.
